Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria
Annals of Hematology · 22.01.2025
DOI: 10.1007/s00277-025-06193-5 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Annals of Hematology, online erschienen am 22.01.2025. Verfasst von Austin Kulasekararaj und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematological Medicine, King's College Hospital, National Institute for Health Research and Wellcome King's Clinical Research Facility…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ravulizumab is a second-generation complement component 5 (C5) inhibitor (C5i) approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) following positive results from two pivotal trials in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH. In both trials, after the 26week primary evaluation period, all patients received ravulizumab for up to 6 years. To report ravulizumab treatment outcomes in patients with PNH originally naive to C5i treatment and eculizumab-experienced patients with PNH treated for up to 6 years. Originally C5i-naive ( N = 244) and eculizumab-experienced ( N = 191) patients with PNH continued ravulizumab treatment for up to 6 years. Major adverse vascular events (MAVEs; including thrombotic events [TEs]) and survival are reported, including a comparison of survival with untreated patients from the International PNH Registry. Laboratory parameters for intravascular hemolysis (IVH) are also described. For up to 6 years (1468.0 patient-years of exposure), ravulizumab provided durable control of terminal complement activity and IVH, resulting in a low incidence of MAVEs (including TEs) reported (MAVE rate: 0.7–1.4 per 100 patient-years) and, compared with untreated patients from the International PNH Registry, reduced the risk of mortality by five-fold. The few breakthrough IVH events reported ( N = 122) were commonly associated with complement-amplifying conditions, and only two events (1.8%) were associated with suboptimal inhibition of C5 (i.e. serum free C5 ≥ 0.5 µg/mL). These results support the long-term use of ravulizumab as the first-line treatment of choice for patients with PNH. Trial registration details: NCT01374360; registered: October 29, 2004; NCT02946463; registered: October 27, 2016; NCT03056040; registered: June 05, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematological Medicine, King's College Hospital, National Institute for Health Research and Wellcome King's Clinical Research Facility and King's College London, London, UK. austin.kulasekararaj@nhs.net.
- Division of Hematology, Johns Hopkins Medicine, Baltimore, MD, USA.
- Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
- Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany.
- St James's Hospital, NHS Teaching Hospitals, Leeds, UK.
- West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Zitieren
APA
Kulasekararaj, A., Brodsky, R., Schrezenmeier, H., Griffin, M., Röth, A., Piatek, C., Ogawa, M., Yu, J., Patel, A. S., Patel, Y., Notaro, R., Usuki, K., Kulagin, A., Gualandro, S., Füreder, W., Peffault de Latour, R., Szer, J., & Lee, J. W. (2025). Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology. https://doi.org/10.1007/s00277-025-06193-5
Vancouver
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Röth A, Piatek C, et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology. 2025. doi:10.1007/s00277-025-06193-5
BibTeX
@article{Kulasekararaj2025,
author = {Kulasekararaj, Austin and Brodsky, Robert and Schrezenmeier, Hubert and Griffin, Morag and Röth, Alexander and Piatek, Caroline and Ogawa, Masayo and Yu, Ji and Patel, Ami S and Patel, Yogesh and Notaro, Rosario and Usuki, Kensuke and Kulagin, Alexander and Gualandro, Sandra and Füreder, Wolfgang and Peffault de Latour, Regis and Szer, Jeff and Lee, Jong Wook},
title = {Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06193-5}
}
EUVIMED